


Organic & Biomolecular Chemistry

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

Metal-Free (Boc)₂O-Mediated C4-Selective Direct

Indolation of Pyridines Using TEMPO

Wen-Bing Qin, Jia-Yi Zhu, Yu-Bo Kong, Yun-Hong Bao,
Zheng-Wang Chen, Liang-Xian Liu*

Key Laboratory of Organo-Pharmaceutical Chemistry of Jiangxi Province, Gannan Normal
University, Ganzhou 341000, PR China

Abstract: Direct metal-free C-4-selective indolation of pyridines is achieved for the first time using TEMPO and (Boc)₂O. A variety of substituents on both indoles and pyridines are tolerated to give 3-(pyridin-4-yl)-1*H*-indole derivatives in moderate to excellent yields. This finding provides a novel approach for developing metal-free C-H functionalizations of pyridines.


Keywords: Indole; TEMPO; Pyridine; (Boc)₂O; Cross-coupling

Introduction

Substituted pyridines are important intermediates in the synthesis of pharmaceuticals and functional materials.¹ In addition, a pyridine core plays a key role in a number of natural products, pharmaceuticals, ligands, and functional materials. However, the presence of electron-withdrawing and Lewis-basic sp² nitrogen limits a repertoire of methods to decorate the heteroaromatic ring.² The chemistry to directly functionalize pyridine remains a significant challenge due to poor chemoselectivity and the lower energy of the π -system relative to benzene.³ As a result, most of the synthetic methods require prefunctionalization, for example by halogenation or metalation, before subsequent coupling reactions owing to the low reactivity of pyridine derivatives towards aromatic electrophilic substitution reactions such as the Friedel-Crafts reaction.⁴

These factors have led to the use of pyridines functionalized at nitrogen to generate cationic pyridinium salts or neutral, but similarly activated, pyridinium ylides. Generally, the direct alkylation and arylation of pyridines were carried out by using derivatives (e.g., *N*-oxides,⁵ and *N*-iminopyridinium ylides⁶) (eq 1). However, this approach necessitates two additional steps: activation of the pyridine starting material, and then unmasking the arylated product. The use of pyridines directly would clearly represent the ideal situation in terms of both cost and simplicity. To tackle such a problem, methodologies for the direct alkylation and arylation of pyridines have been developed. Recently, transition-metal-catalyzed pyridyl C-H functionalizations have received intensive attention. Accordingly, significant progress in this field has been achieved.⁷⁻¹² More recently, Knochel and co-workers reported a novel transition-metal-free BF₃ • OEt₂ mediated regioselective synthesis of 4-substituted pyridine derivatives using LiCl activated Grignard or organozinc reagents. Despite such progress, the direct indolation of pyridines still remained elusive (eq 3).¹³ As a solution, we report a novel metal-free regioselective direct indolation of pyridines using TEMPO and (Boc)₂O.

We commenced our study with the reaction of **1a** with pyridine and TBHP as oxidant (Table 1). To our delight, the reaction in (Boc)₂O at rt for 24 h afforded the desired product **3a** in 17% yield (entry 1). To our knowledge, this is the first example of a metal-free regioselective direct synthesis of *tert*-butyl 3-(pyridin-4-yl)-1*H*-indole-1-carboxylate using (Boc)₂O as activating agent. Hannah and co-workers reported a chemoselective four-step Suzuki reaction towards 6-bromo-3-(pyridin-4-yl)-1*H*-indole, which was found to be an IMPDA inhibitor.¹⁴



Scheme 1. Regioselective direct alkylation and arylation of pyridines.

Table 1. Optimization of reaction conditions^a


Entry	Oxidant (equiv)	(Boc) ₂ O (equiv)	Temp (°C)	Yield (%) ^b
1	TBHP (2.0)	2.0	25	17
2	H ₂ O ₂ (2.0)	2.0	25	0
3	DDQ (1.2)	2.0	25	23
4	TEMPO (0.3)	2.0	25	35
5	-	2.0	25	trace
6	TEMPO (0.3)	2.0	0	36
7	TEMPO (0.3)	2.0	10	45
8	TEMPO (0.3)	2.0	35	23
9	TEMPO (0.3)	2.0	45	trace
10	TEMPO (0.2)	-	10	0
11	TEMPO (0.6)	2.0	10	62
12	TEMPO (0.7)	2.0	10	80
13	TEMPO (0.8)	2.0	10	78
14	TEMPO (0.7)	1.0	10	36
15	TEMPO (0.7)	1.5	10	70
16	TEMPO (0.7)	2.5	10	79

^a Reaction conditions: indole (0.5 mmol), pyridine (0.8 mmol).
^b Isolated yield.

Encouraged by this finding, we continued our investigations by optimizing the reaction conditions (Table 1). A screen of oxidants showed that TEMPO was more efficient than TBHP, H₂O₂, and DDQ (entries 1-4). In contrast to TEMPO, when H₂O₂ was used this transformation did not occur. Besides, only a trace amount of desired product was detected when the reaction was performed in the absence of TEMPO (entry 5). The influence of the solvent was also studied. When other solvents, such as benzene, toluene, DCM, and THF, were applied, a trace or none of the desired

product was observed. To our delight, the yield of **3a** was improved to 62% when the reaction was carried out in the absence of solvent at 10 °C (entry 11). Control experiments indicated that (Boc)₂O is essential for this transformation (entry 10). After extensive screening on other parameters (see the Supporting Information, Table S1), we found that the indolation of pyridine by using TEMPO (70 mol %) in air as an oxidant and pyridine (160 mol %) in (Boc)₂O (200 mol %) at 10 °C led to the highest efficiency (80% yield, entry 12).

Table 2 Oxidative coupling reaction of indoles with pyridines.^a



Entry	R ¹	R ²	Product	t (h)	Yield (%) ^b
1	H	H	3a	24	80
2	5-F	H	3b	24	75
3	5-Br	H	3c	24	71
4	5-Me	H	3d	24	82
5	5-OMe	H	3e	24	80
6	5-OBn	H	3f	24	76
7	5-CN	H	3g	36	56
8	6-F	H	3h	24	77
9	6-Cl	H	3i	24	72
10	6-OBn	H	3j	24	79
11	6-CO ₂ Me	H	3k	24	60
12	7-Cl	H	3l	24	80
13	7-Me	H	3m	24	84
14	7-OBn	H	3n	24	88
15	7-NO ₂	H	3o	36	46
16	2-Me	H	3p	30	75
17	2-Ph	H	3q	30	90
18	H	3-CN	3r	24	74
19	5-F	2-(<i>p</i> -Cl-Bn)	3s	48	57
20	5-Me	2-Bn	3t	48	68
21	5-Me	2-(<i>p</i> -Cl-Bn)	3u	48	56
22	6-F	2-(<i>p</i> -Cl-Bn)	3v	48	70
23	6-F	2-Bn	3w	48	65
24	H	2-CH ₃	3x	48	trace

^a Reaction conditions: indole (0.5 mmol), pyridine (0.8 mmol), TEMPO (0.35 mmol), (Boc)₂O (1.0 mmol).

^b Isolated yield.


With optimized conditions established we explored the scope of the reaction (Table 2). First, a series of substituted indoles were subjected to react with pyridine (entries 1-17). The reaction can tolerate a variety of functional groups at the 2, 5, 6, and 7 positions of indoles, such as F, Cl, Br, CH₃, CH₃O, Ph, BnO, CO₂CH₃, CN, and NO₂. The substituent effect on the indole ring was then investigated. Electron-rich and electron-neutral indoles gave reaction products in good to excellent yields. Electron-donating substituents showed better results than electron-withdrawing substituents in this transformation. For example, 7-benzyloxy-1*H*-indole was transformed into **3n** in 88% yield (entry 14). Interestingly, we observed indoles with strong electron-withdrawing substituents at the 5 and 7 positions of indoles, such as CN and NO₂, could provide the corresponding products with lower yields (entries 7 and 15). Sterically encumbered 2-substituted indoles also proceeded in good to excellent yield, though extended reaction times were required (entries 16 and 17). Treatment of **3c** with a methanolic solution of hydrochloric acid at room

temperature gave the N-Boc-deprotection product **4**, which was confirmed by X-ray crystallography (see Supporting Information).


Subsequently, the substrate scope of pyridines was then investigated (entries 18-23). Pyridines with a substituent at C-2 or C-3 on the pyridyl ring could undergo the expected C-4 coupling reaction in moderate yields. When using the pyridine with an electron-withdrawing cyano group at the C-3 position as a coupling partner (entry 18), the yield was obviously higher than those using C-2 substituted pyridines (entries 19-23). Unexpectedly, only a trace amount of **3x** was detected when 2-methylpyridine was used as a coupling partner (entry 24).

The protocol of the present reaction was very simple: the substrate, reagent, and catalyst were stirred together in simple glassware. Thus, this reaction could be applied to a large-scale synthesis without any difficulties. When the reaction of indole (1.17 g, 10 mmol) was performed with pyridine (1.26 g, 15.9 mmol), (Boc)₂O (4.36 g, 20 mmol), and TEMPO (1.09 g, 7 mmol) under the optimized reaction conditions for 24 h, the desired product was obtained in 81% yield.

Some control experiments were also established. While employing pyridine with a phenyl group at the C-4 position as coupling partner, it did not afford the expected 3-pyridylindole **6a**, only the dihydropyridine N-Boc **6b** was obtained in good yield (Scheme 2). Similarly, when isoquinoline was subjected to the standard reaction conditions, the additive products **8** were obtained in good yields (Scheme 3). In addition, when H₂O was added, a significant decrease in the yield of **3a** was observed (see Supporting Information).




Scheme 2. Addition of indole to 4-phenyl pyridine.




Scheme 3. Addition of indole to isoquinoline.

We next initiated studies to gain more detailed insights into the role of (Boc)₂O in the cross-coupling. Under optimized conditions, N-Boc indole **9** was chosen as a substrate instead of indole. To our surprise, no conversion was observed (Scheme 4), indicating that the substituents at the N1-position of the indole had a great influence on the reactivity.



Scheme 4. Reaction of *N*-Boc indole **9** with pyridine.

Although the exact mechanism of this cross-coupling reaction is still not clear, based on these preliminary results and previous reports in literature,¹³ a tentative reaction path is proposed in Scheme 5. In the initial step, treatment of **2a** with (Boc)₂O affords the intermediate **10**. Subsequent addition of **10** to indole leads to the intermediate **11**, which is converted into the the intermediate **12** by C-3 proton elimination from the indole ring. Finally, **12** undergoes aromatization to afford the corresponding product **3a**.



Scheme 5. A plausible pathway for the formation of **3a**.

Conclusions

In conclusion, the metal-free direct indolation of pyridines by TEMPO and (Boc)₂O has been realized. This reaction has revealed an efficient and new strategic way to access 3-(pyridin-4-yl)-1*H*-indole derivatives from readily available starting materials in one step. The protocol was very simple, and tolerate an array of functional groups at the 2, 5, 6, and 7 positions of indoles, including F, Cl, Br, CH₃, CH₃O, Ph, BnO, CO₂CH₃, CN, and NO₂ groups. In addition, all the reagents could be used without purification, and the reaction could be readily applied to alarge-scale synthesis without any difficulties. Importantly, our findings further encouraged us to design and explore such a dehydrogenation based on cross-coupling because it has great potential in enabling the rapid construction of functionalized compounds from simple starting materials in an atom- and step-economical fashion.

Experimental Section

General

Melting points were determined on a digital melting point apparatus and temperatures were uncorrected. Infrared spectra were measured with a Nicolet Avatar 360 FT-IR spectrometer using film KBr pellet techniques. ¹H and ¹³C NMR spectra were recorded on a Bruker spectrometers at 400 and 100 MHz, respectively. Chemical shifts were reported in ppm relative to TMS for ¹H and ¹³C NMR spectra. CDCl₃ or DMSO-*d*₆ was used as the NMR solvent. Mass spectra were recorded with Bruker Dalton Esquire 3000 plus LC-MS apparatus. Elemental analysis were carried out on a Perkin-Elmer 240B instrument. HRFABMS spectra were recorded on a FTMS apparatus. Silica gel (300-400 mesh) was used for flash column chromatography, eluting (unless otherwise stated) with an ethyl acetate/petroleum ether (PE) (60-90 °C) mixture.

General Procedure for the Indolation of Pyridines.

To a solution of indole (0.5 mmol) and TEMPO (0.35 mmol) in pyridine (0.8 mmol) was added (Boc)₂O (1.0 mmol) under air atmosphere and the mixture was stirred at 10 °C for 24-48 h. The

reaction mixture was concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (eluent: EtOAc/PE = 1:4) to yield the corresponding product.

tert-Butyl 3-(pyridin-4-yl)-1*H*-indole-1-carboxylate (**3a**). *Rf* 0.25 (EtOAc/PE = 1/4). White solid, m.p. 90.3-91.8 °C. IR (KBr) ν_{\max} : 1727, 1378, 1243, 1160, 756 cm^{-1} . ^1H NMR (400 MHz, CDCl_3): δ 8.70 (d, $J = 5.8$ Hz, 2H, Ar-H), 8.26 (d, $J = 8.0$ Hz, 1H, Ar-H), 7.89 (s, 1H, Ar-H), 7.87 (d, $J = 8.0$ Hz, 1H, Ar-H), 7.59 (d, $J = 5.8$ Hz, 2H, Ar-H), 7.43 (t, $J = 7.5$ Hz, 1H, Ar-H), 7.35 (t, $J = 7.5$ Hz, 1H, Ar-H), 1.73 (s, 9H, 3XCH₃). ^{13}C NMR (100 MHz, CDCl_3): δ 150.3, 149.4, 141.8, 136.0, 127.9, 125.1, 124.4, 123.4, 122.2, 119.6, 119.4, 115.7, 84.5, 28.2. HRESIMS calcd for $[\text{C}_{18}\text{H}_{18}\text{N}_2\text{O}_2 + \text{H}]^+$ 295.14465 (100%), found 295.14389 (100%).

tert-Butyl 5-fluoro-3-(pyridin-4-yl)-1*H*-indole-1-carboxylate (**3b**). *Rf* 0.20 (EtOAc/PE = 1/4). White solid, m.p. 139-140 °C. IR (KBr) ν_{\max} : 1737, 1598, 1464, 1377, 1258, 1152, 1098, 1051, 804 cm^{-1} . ^1H NMR (400 MHz, CDCl_3): δ 8.71 (s, 2H, Ar-H), 8.22-8.17 (m, 1H, Ar-H), 7.90 (s, 1H, Ar-H), 7.54 (d, $J = 5.6$ Hz, 2H, Ar-H), 7.50 (dd, $J = 9.1, 2.6$ Hz, 1H, Ar-H), 7.14 (dt, $J = 2.6, 9.1$ Hz, 1H, Ar-H), 1.72 (s, 9H, 3XCH₃). ^{13}C NMR (100 MHz, CDCl_3): δ 159.7 (d, $J = 240.2$ Hz), 150.4, 149.1, 141.3, 132.4, 128.8 (d, $J = 9.6$ Hz), 125.7, 122.0, 119.1 (d, $J = 4.2$ Hz), 116.7 (d, $J = 9.1$ Hz), 112.9 (d, $J = 25.0$ Hz), 105.3 (d, $J = 24.7$ Hz), 84.8, 28.1. HRESIMS calcd for $[\text{C}_{18}\text{H}_{17}\text{FN}_2\text{O}_2 + \text{H}]^+$ 313.13523 (100%), found 313.13361 (100%).

tert-Butyl 5-bromo-3-(pyridin-4-yl)-1*H*-indole-1-carboxylate (**3c**). *Rf* 0.20 (EtOAc/PE = 1:4). Pale yellow, m.p. 130.7-132.6 °C. IR (KBr) ν_{\max} : 1744, 1379, 1245, 1160, 756 cm^{-1} . ^1H NMR (400 MHz, CDCl_3): δ 8.70 (d, $J = 6.0$ Hz, 2H, Ar-H), 8.13 (d, $J = 8.8$ Hz, 1H, Ar-H), 7.96 (d, $J = 1.8$ Hz, 1H, Ar-H), 7.86 (s, 1H, Ar-H), 7.54 (d, $J = 6.0$ Hz, 1H, Ar-H), 7.52 (d, $J = 6.0$ Hz, 1H, Ar-H), 7.50 (dd, $J = 8.8, 1.8$ Hz, 1H, Ar-H), 1.72 (s, 9H, 3XCH₃). ^{13}C NMR (100 MHz, CDCl_3): δ 150.4, 149.0, 141.1, 134.7, 129.6, 128.0, 125.3, 122.3, 122.2, 118.7, 117.1, 116.9, 85.0, 28.2. HRESIMS calcd for $[\text{C}_{18}\text{H}_{17}\text{BrN}_2\text{O}_2 + \text{H}]^+$ 373.05517 (100%), 375.05312 (100%), found 373.05420 (100%), 375.05197 (100%).

tert-Butyl 5-methyl-3-(pyridin-4-yl)-1*H*-indole-1-carboxylate (**3d**). *Rf* 0.20 (EtOAc/PE = 1/4). White solid, m.p. 124-125 °C. IR (KBr) ν_{\max} : 1725, 1601, 1371, 1243, 1150 cm^{-1} . ^1H NMR (400 MHz, CDCl_3): δ 8.70 (d, $J = 5.7$ Hz, 2H, Ar-H), 8.12 (d, $J = 8.3$ Hz, 1H, Ar-H), 7.84 (s, 1H, Ar-H), 7.65 (s, 1H, Ar-H), 7.59 (d, $J = 5.7$ Hz, 2H, Ar-H), 7.24 (d, $J = 8.3$ Hz, 1H, Ar-H), 2.51 (s, 3H, CH₃), 1.72 (s, 9H, 3XCH₃). ^{13}C NMR (100 MHz, CDCl_3): δ 150.2, 149.5, 141.9, 134.2, 133.0, 128.1, 126.4, 124.4, 122.3, 119.5, 119.1, 115.3, 84.3, 28.2, 21.5. HRESIMS calcd for $[\text{C}_{19}\text{H}_{20}\text{N}_2\text{O}_2 + \text{H}]^+$ 309.16030 (100%), found 309.15875 (100%).

tert-Butyl 5-methoxy-3-(pyridin-4-yl)-1*H*-indole-1-carboxylate (**3e**). *Rf* 0.40 (EtOAc/PE = 1/2). White solid, m.p. 106-107 °C. IR (KBr) ν_{\max} : 1723, 1608, 1385, 1249, 1164, 1115 cm^{-1} . ^1H NMR (400 MHz, CDCl_3): δ 8.85-8.60 (br s, 2H, Ar-H), 8.14 (d, $J = 9.0$ Hz, 1H, Ar-H), 7.85 (s, 1H, Ar-H), 7.63-7.54 (br s, 2H, Ar-H), 7.30 (d, $J = 2.5$ Hz, 1H, Ar-H), 7.04 (dd, $J = 9.0, 2.5$ Hz, 1H, Ar-H), 3.90 (s, 3H, OCH₃), 1.72 (s, 9H, 3XCH₃). ^{13}C NMR (100 MHz, CDCl_3): δ 156.5, 150.3, 149.4, 141.9, 130.7, 128.8, 125.0, 122.3, 119.2, 116.4, 113.6, 102.5, 84.3, 55.8, 28.2. HRESIMS calcd for $[\text{C}_{19}\text{H}_{20}\text{N}_2\text{O}_3 + \text{H}]^+$ 325.15522 (100%), found 325.15341 (100%).

tert-Butyl 5-(benzyloxy)-3-(pyridin-4-yl)-1*H*-indole-1-carboxylate (**3f**). *Rf* 0.40 (EtOAc/PE = 1/2). White solid, m.p. 136-137 °C. IR (KBr) ν_{\max} : 1730, 1605, 1371, 1225, 1156, 816 cm^{-1} . ^1H NMR (400 MHz, CDCl_3): δ 8.73 (s, 2H, Ar-H), 8.14 (d, $J = 8.7$ Hz, 1H, Ar-H), 7.85 (s, 1H, Ar-H), 7.56-7.48 (m, 4H, Ar-H), 7.43 (dt, $J = 6.1, 1.6$ Hz, 2H, Ar-H), 7.39-7.35 (m, 2H, Ar-H), 7.12 (dd, $J = 9.1, 2.4$ Hz, 1H, Ar-H), 5.16 (s, 2H, OCH₂), 1.72 (s, 9H, 3XCH₃). ^{13}C NMR (100 MHz, CDCl_3):

δ 155.5, 150.2, 149.4, 141.9, 137.1, 130.9, 128.7, 128.6, 128.0, 127.5, 125.0, 122.1, 119.2, 116.4, 114.3, 104.2, 84.4, 70.8, 28.2. HRESIMS calcd for $[\text{C}_{25}\text{H}_{24}\text{N}_2\text{O}_3 + \text{H}]^+$ 401.18652 (100%), found 401.18503 (100%).

tert-Butyl 5-cyano-3-(pyridin-4-yl)-1*H*-indole-1-carboxylate (**3g**). *Rf* 0.20 (EtOAc/PE = 1/4). Pale yellow solid, m.p. 144-145 °C. IR (KBr) ν_{max} : 2225, 1743, 1603, 1465, 1372, 1289, 1254, 1157, 815 cm^{-1} . ^1H NMR (400 MHz, CDCl_3): δ 8.77 (s, 2H, Ar-H), 8.38 (d, $J = 8.7$ Hz, 1H, Ar-H), 8.18 (d, $J = 1.3$ Hz, 1H, Ar-H), 7.97 (s, 1H, Ar-H), 7.68 (dd, $J = 8.7, 1.3$ Hz, 1H, Ar-H), 7.56 (s, 1H, Ar-H), 7.55 (s, 1H, Ar-H), 1.74 (s, 9H, 3XCH₃). ^{13}C NMR (100 MHz, CDCl_3): δ 150.6, 148.7, 140.4, 137.8, 128.1, 128.0, 126.2, 124.6, 122.3, 119.4, 119.3, 116.6, 107.0, 85.8, 28.1. MS (ESI): 320 ($\text{M}+\text{H}^+$, 100). Anal calcd for $\text{C}_{19}\text{H}_{17}\text{N}_3\text{O}_2$: C, 71.46; H, 5.37; N, 13.16. Found C, 71.27; H, 5.63; N, 12.85.

tert-Butyl 6-fluoro-3-(pyridin-4-yl)-1*H*-indole-1-carboxylate (**3h**). *Rf* 0.20 (EtOAc/PE = 1/4). White solid, m.p. 113-114 °C. IR (KBr) ν_{max} : 1731, 1601, 1483, 1444, 1388, 1252, 1167, 807 cm^{-1} . ^1H NMR (400 MHz, CDCl_3): δ 8.71 (d, $J = 4.8$ Hz, 2H, Ar-H), 7.98 (dd, $J = 8.8, 1.4$ Hz, 1H, Ar-H), 7.85 (s, 1H, Ar-H), 7.76 (dd, $J = 8.8, 5.3$ Hz, 1H, Ar-H), 7.56 (dd, $J = 4.8, 1.4$ Hz, 2H, Ar-H), 7.10 (dt, $J = 2.4, 8.8$ Hz, 1H, Ar-H), 1.72 (s, 9H, 3XCH₃). ^{13}C NMR (100 MHz, CDCl_3): δ 161.2 (d, $J = 240.7$ Hz), 150.4, 149.1, 141.4, 136.3 (d, $J = 12.8$ Hz), 124.4 (d, $J = 3.6$ Hz), 124.3, 122.1, 120.4 (d, $J = 10.0$ Hz), 119.3, 117.0 (d, $J = 24.3$ Hz), 103.0 (d, $J = 28.6$ Hz), 84.9, 28.1. HRESIMS calcd for $[\text{C}_{18}\text{H}_{17}\text{FN}_2\text{O}_2 + \text{H}]^+$ 313.13523 (100%), found 313.13358 (100%).

tert-Butyl 6-chloro-3-(pyridin-4-yl)-1*H*-indole-1-carboxylate (**3i**). *Rf* 0.30 (EtOAc/PE = 1/4). White solid, m.p. 164-165 °C. IR (KBr) ν_{max} : 1729, 1600, 1463, 1437, 1382, 1252, 1171, 805 cm^{-1} . ^1H NMR (400 MHz, CDCl_3): δ 8.70 (d, $J = 5.9$ Hz, 2H, Ar-H), 8.30 (s, 1H, Ar-H), 7.85 (s, 1H, Ar-H), 7.76 (d, $J = 8.5$ Hz, 1H, Ar-H), 7.55 (d, $J = 5.9$ Hz, 2H, Ar-H), 7.32 (dd, $J = 8.5, 1.9$ Hz, 1H, Ar-H), 1.73 (s, 9H, 3XCH₃). ^{13}C NMR (100 MHz, CDCl_3): δ 150.4, 149.0, 141.2, 136.4, 131.1, 126.4, 124.7, 124.0, 122.2, 120.4, 119.3, 116.0, 85.1, 28.1. HRESIMS calcd for $[\text{C}_{18}\text{H}_{17}\text{ClN}_2\text{O}_2 + \text{H}]^+$ 329.10568 (100%), 331.10273 (33%), found 329.10403 (100%), 331.10080 (33%).

tert-Butyl 6-(benzyloxy)-3-(pyridin-4-yl)-1*H*-indole-1-carboxylate (**3j**). *Rf* 0.38 (EtOAc/PE = 1/2). White solid, m.p. 135-136 °C. IR (KBr) ν_{max} : 1733, 1601, 1374, 1227, 1152, 815 cm^{-1} . ^1H NMR (400 MHz, CDCl_3): δ 8.68 (s, 2H, Ar-H), 7.94 (s, 1H, Ar-H), 7.78 (s, 1H, Ar-H), 7.74 (d, $J = 8.7$ Hz, 1H, Ar-H), 7.58 (d, $J = 4.3$ Hz, 2H, Ar-H), 7.51 (dd, $J = 8.4, 1.3$ Hz, 2H, Ar-H), 7.44 (dt, $J = 1.3, 8.4$ Hz, 2H, Ar-H), 7.37 (dt, $J = 2.4, 8.4$ Hz, 1H, Ar-H), 7.07 (dd, $J = 8.7, 2.4$ Hz, 1H, Ar-H), 5.19 (s, 1H, OCH₂), 1.71 (s, 9H, 3XCH₃). ^{13}C NMR (100 MHz, CDCl_3): δ 157.4, 150.2, 149.5, 141.9, 137.1, 136.9, 128.6, 128.0, 127.6, 123.1, 122.2, 121.9, 120.2, 119.4, 113.4, 100.9, 84.3, 70.5, 28.2. HRESIMS calcd for $[\text{C}_{25}\text{H}_{24}\text{N}_2\text{O}_3 + \text{H}]^+$ 401.18652 (100%), found 401.18460 (100%).

1-*tert*-Butyl 6-methyl 3-(pyridin-4-yl)-1*H*-indole-1,6-dicarboxylate (**3k**). *Rf* 0.30 (EtOAc/PE = 1/2). Pale yellow solid, m.p. 135-137 °C. IR (KBr) ν_{max} : 1740, 1717, 1604, 1438, 1377, 1298, 1241, 1189, 1155, 1100 cm^{-1} . ^1H NMR (400 MHz, CDCl_3): δ 8.97 (s, 1H, Ar-H), 8.73 (dd, $J = 5.9, 1.4$ Hz, 2H, Ar-H), 8.05 (dd, $J = 8.4, 1.4$ Hz, 1H, Ar-H), 8.02 (s, 1H, Ar-H), 7.89 (d, $J = 8.4$ Hz, 1H, Ar-H), 7.58 (d, $J = 5.9$ Hz, 2H, Ar-H), 3.99 (s, 3H, OCH₃), 1.75 (s, 9H, 3XCH₃). ^{13}C NMR (100 MHz, CDCl_3): δ 167.3, 150.4, 149.0, 141.1, 135.5, 131.5, 127.0, 126.8, 124.5, 112.2, 119.4, 119.3, 117.6, 85.2, 52.2, 28.1. MS (ESI): 353 ($\text{M}+\text{H}^+$, 100). Anal calcd for $\text{C}_{20}\text{H}_{20}\text{N}_2\text{O}_4$: C, 68.17; H, 5.72; N, 7.95. Found C, 67.83; H, 6.01; N, 7.72.

tert-Butyl 7-chloro-3-(pyridin-4-yl)-1*H*-indole-1-carboxylate (**3l**). *Rf* 0.30 (EtOAc/PE = 1/2).

Amorphous solid. IR (KBr) ν_{\max} : 1753, 1605, 1353, 1266, 1152 cm^{-1} . ^1H NMR (400 MHz, CDCl_3): δ 8.71 (s, 2H, Ar-H), 7.80 (s, 1H, Ar-H), 7.75 (dd, $J = 7.9, 0.9$ Hz, 1H, Ar-H), 7.54 (d, $J = 7.9$ Hz, 2H, Ar-H), 7.43 (dd, $J = 7.9, 0.9$ Hz, 1H, Ar-H), 7.27 (t, $J = 7.9$ Hz, 1H, Ar-H), 1.70 (s, 9H, 3XCH_3). ^{13}C NMR (100 MHz, CDCl_3): δ 150.3, 148.5, 141.2, 132.9, 131.4, 127.8, 127.2, 124.3, 122.4, 121.0, 119.2, 118.2, 85.2, 27.9. MS (ESI): 329 ($\text{M}+\text{H}^+$, 100), 331 ($\text{M}+\text{H}^+$, 30). Anal calcd for $\text{C}_{18}\text{H}_{17}\text{ClN}_2\text{O}_2$: C, 65.75; H, 5.21; N, 8.52. Found C, 65.61; H, 5.36; N, 8.20.

tert-Butyl 7-methyl-3-(pyridin-4-yl)-1*H*-indole-1-carboxylate (**3m**). *Rf* 0.35 (EtOAc/PE = 1/2). Amorphous solid. IR (KBr) ν_{\max} : 1750, 1604, 1355, 1260, 1225, 1152 cm^{-1} . ^1H NMR (400 MHz, CDCl_3): δ 8.70 (s, 2H, Ar-H), 7.77 (s, 1H, Ar-H), 7.68 (d, $J = 7.5$ Hz, 1H, Ar-H), 7.57 (d, $J = 5.6$ Hz, 2H, Ar-H), 7.27 (t, $J = 7.5$ Hz, 1H, Ar-H), 7.22 (d, $J = 5.6$ Hz, 1H, Ar-H), 2.68 (s, 3H, CH_3), 1.69 (s, 9H, 3XCH_3). ^{13}C NMR (100 MHz, CDCl_3): δ 150.2, 149.2, 141.9, 135.6, 129.3, 128.4, 126.6, 126.0, 123.8, 122.5, 119.5, 117.1, 84.1, 28.0, 22.1. MS (ESI): 309 ($\text{M}+\text{H}^+$, 100). Anal calcd for $\text{C}_{19}\text{H}_{20}\text{N}_2\text{O}_2$: C, 74.00; H, 6.54; N, 9.08. Found C, 73.63; H, 6.91; N, 8.71.

tert-Butyl 7-(benzyloxy)-3-(pyridin-4-yl)-1*H*-indole-1-carboxylate (**3n**). *Rf* 0.38 (EtOAc/PE = 1/2). White solid, m.p. 112-113 $^{\circ}\text{C}$. IR (KBr) ν_{\max} : 1744, 1604, 1366, 1239, 1152, 1047 cm^{-1} . ^1H NMR (400 MHz, CDCl_3): δ 8.68 (s, 2H, Ar-H), 7.77 (s, 1H, Ar-H), 7.58 (d, $J = 7.1$ Hz, 2H, Ar-H), 7.56 (d, $J = 8.5$ Hz, 2H, Ar-H), 7.48 (dd, $J = 7.1, 1.0$ Hz, 1H, Ar-H), 7.40 (dt, $J = 1.0, 8.5$ Hz, 2H, Ar-H), 7.36 (dt, $J = 1.0, 7.1$ Hz, 1H, Ar-H), 7.28 (t, $J = 8.0$ Hz, 1H, Ar-H), 6.99 (d, $J = 8.0$ Hz, 1H, Ar-H), 5.27 (s, 2H, OCH_2), 1.58 (s, 9H, 3XCH_3). ^{13}C NMR (100 MHz, CDCl_3): δ 150.2, 148.9, 147.9, 141.9, 137.0, 130.9, 128.4, 127.8, 127.5, 127.0, 125.9, 124.5, 122.3, 119.1, 112.5, 109.0, 84.1, 71.1, 27.8. MS (ESI): 401 ($\text{M}+\text{H}^+$, 100). Anal calcd for $\text{C}_{25}\text{H}_{24}\text{N}_2\text{O}_3$: C, 74.98; H, 6.04; N, 7.00. Found C, 74.67; H, 6.32; N, 6.86.

tert-Butyl 7-nitro-3-(pyridin-4-yl)-1*H*-indole-1-carboxylate (**3o**). *Rf* 0.20 (EtOAc/PE = 1/2). Yellow solid, m.p. 116-118 $^{\circ}\text{C}$. IR (KBr) ν_{\max} : 1745, 1606, 1531, 1371, 1259, 1149, 818 cm^{-1} . ^1H NMR (400 MHz, CDCl_3): δ 8.75 (s, 2H, Ar-H), 8.08 (dd, $J = 8.0, 0.8$ Hz, 1H, Ar-H), 7.91 (s, 1H, Ar-H), 7.88 (dd, $J = 8.0, 0.8$ Hz, 1H, Ar-H), 7.56 (d, $J = 8.0$ Hz, 2H, Ar-H), 7.45 (t, $J = 8.0$ Hz, 1H, Ar-H), 1.65 (s, 9H, 3XCH_3). ^{13}C NMR (100 MHz, CDCl_3): δ 150.5, 148.3, 140.5, 139.5, 131.6, 127.8, 126.2, 124.6, 123.1, 122.5, 120.9, 119.5, 86.8, 27.9. MS (ESI): 340 ($\text{M}+\text{H}^+$, 100), 362 ($\text{M}+\text{Na}^+$, 15). Anal calcd for $\text{C}_{18}\text{H}_{17}\text{N}_3\text{O}_4$: C, 63.71; H, 5.05; N, 12.38. Found C, 63.98; H, 4.89; N, 12.02.

tert-Butyl 2-methyl-3-(pyridin-4-yl)-1*H*-indole-1-carboxylate (**3p**). *Rf* 0.20 (EtOAc/PE = 1/6). Pale yellow solid, m.p. 80-81 $^{\circ}\text{C}$. IR (KBr) ν_{\max} : 1736, 1603, 1358, 1319, 1152, 1119, 834 cm^{-1} . ^1H NMR (400 MHz, CDCl_3): δ 8.73 (s, 2H, Ar-H), 8.19 (d, $J = 8.4$ Hz, 1H, Ar-H), 7.49 (d, $J = 7.6$ Hz, 1H, Ar-H), 7.40 (d, $J = 7.6$ Hz, 2H, Ar-H), 7.33 (dt, $J = 1.0, 7.6$ Hz, 1H, Ar-H), 7.25 (dt, $J = 8.4, 1.0$ Hz, 1H, Ar-H), 2.65 (s, 3H, CH_3), 1.74 (s, 9H, 3XCH_3). ^{13}C NMR (100 MHz, CDCl_3): δ 150.5, 150.0, 142.4, 135.8, 134.8, 128.3, 125.0, 124.1, 123.1, 118.5, 118.2, 115.6, 84.3, 28.3, 14.8. MS (ESI): 309 ($\text{M}+\text{H}^+$, 100). Anal calcd for $\text{C}_{19}\text{H}_{20}\text{N}_2\text{O}_2$: C, 74.00; H, 6.54; N, 9.08. Found C, 73.88; H, 6.73; N, 8.89.

tert-Butyl 2-phenyl-3-(pyridin-4-yl)-1*H*-indole-1-carboxylate (**3q**). *Rf* 0.31 (EtOAc/PE = 1/4). Pale yellow solid, m.p. 136-138 $^{\circ}\text{C}$. IR (KBr) ν_{\max} : 1727, 1604, 1357, 1321, 1154 cm^{-1} . ^1H NMR (400 MHz, CDCl_3): δ 8.52 (d, $J = 3.4$ Hz, 2H, Ar-H), 8.35 (d, $J = 8.4$ Hz, 1H, Ar-H), 7.63 (d, $J = 7.8$ Hz, 1H, Ar-H), 7.44 (dt, $J = 1.2, 7.3$ Hz, 1H, Ar-H), 7.39-7.31 (m, 4H, Ar-H), 7.30-7.26 (m, 2H, Ar-H), 7.15 (d, $J = 5.9$ Hz, 2H, Ar-H), 1.28 (s, 9H, 3XCH_3). ^{13}C NMR (100 MHz, CDCl_3): δ 149.9, 149.6, 142.0, 136.9, 136.6, 133.2, 130.2, 130.1, 128.1, 128.0, 125.1, 124.8, 124.7, 123.4,

119.0, 115.5, 83.8, 27.5. MS (ESI): 371 (M+H⁺, 100). Anal calcd for C₂₄H₂₂N₂O₂: C, 77.81; H, 5.99; N, 7.56. Found C, 77.65; H, 6.18; N, 7.39.

tert-Butyl 3-(3-cyanopyridin-4-yl)-1*H*-indole-1-carboxylate (**3r**). *R*_f 0.33 (EtOAc/PE = 1/4). Pale yellow solid, m.p. 116-118 °C. IR (KBr) ν_{\max} : 2231, 1725, 1608, 1374, 1259, 1160, 1094, 1055, 798 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 9.15 (s, 2H, Ar-H), 8.30 (d, *J* = 8.3 Hz, 1H, Ar-H), 8.22 (s, 1H, Ar-H), 7.95-7.80 (br s, 1H, Ar-H), 7.72 (d, *J* = 7.9 Hz, 1H, Ar-H), 7.47 (dt, *J* = 0.9, 8.3 Hz, 1H, Ar-H), 7.38 (dt, *J* = 0.9, 7.9 Hz, 1H, Ar-H), 1.73 (s, 9H, 3XCH₃). ¹³C NMR (100 MHz, CDCl₃): δ 153.9, 152.0, 149.0, 145.1, 135.7, 127.4, 126.9, 125.6, 123.7, 119.2, 116.9, 115.9, 115.4, 85.1, 28.1. MS (ESI): 320 (M+H⁺, 100). Anal calcd for C₁₉H₁₇N₃O₂: C, 71.46; H, 5.37; N, 13.16. Found C, 71.20; H, 5.61; N, 12.83.

tert-Butyl 3-(2-(4-chlorobenzyl)pyridin-4-yl)-5-fluoro-1*H*-indole-1-carboxylate (**3s**). *R*_f 0.25 (EtOAc/PE = 1/6). Pale yellow solid, m.p. 131-133 °C. IR (KBr) ν_{\max} : 1725, 1609, 1374, 1260, 1161, 798 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 8.64 (d, *J* = 5.2 Hz, 1H, Ar-H), 8.18 (dd, *J* = 8.5, 4.1 Hz, 1H, Ar-H), 7.86 (s, 1H, Ar-H), 7.41 (dd, *J* = 8.9, 2.4 Hz, 1H, Ar-H), 7.38 (dd, *J* = 4.1, 1.6 Hz, 1H, Ar-H), 7.35 (s, 1H, Ar-H), 7.31 (d, *J* = 8.5 Hz, 1H, Ar-H), 7.30 (s, 1H, Ar-H), 7.29-7.26 (m, 2H, Ar-H), 7.13 (dd, *J* = 8.9, 2.4 Hz, 1H, Ar-H), 4.21 (s, 2H, CH₂), 1.71 (s, 9H, 3XCH₃). ¹³C NMR (100 MHz, CDCl₃): δ 161.1, 159.6 (d, *J* = 240.1 Hz), 150.1, 149.3 (d, *J* = 30.5 Hz), 142.0, 137.9, 136.7, 132.4, 130.4, 128.8, 128.7, 125.7, 121.4, 119.9, 119.2 (d, *J* = 4.1 Hz), 116.7 (d, *J* = 9.2 Hz), 112.9 (d, *J* = 25.0 Hz), 105.3 (d, *J* = 24.7 Hz), 84.8, 44.0, 28.1. MS (ESI): 437 (M+H⁺, 100), 439 (M+H⁺, 30). Anal calcd for C₂₅H₂₂ClFN₂O₂: C, 68.73; H, 5.08; N, 6.41. Found C, 68.39; H, 5.37; N, 6.14.

tert-Butyl 3-(3-benzylpyridin-4-yl)-5-methyl-1*H*-indole-1-carboxylate (**3t**). *R*_f 0.19 (EtOAc/PE = 1/8). Amorphous solid. IR (KBr) ν_{\max} : 1735, 1372, 1248, 1156 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 8.64 (d, *J* = 5.2 Hz, 1H, Ar-H), 8.09 (d, *J* = 8.3 Hz, 1H, Ar-H), 7.80 (s, 1H, Ar-H), 7.49 (s, 1H, Ar-H), 7.42 (dd, *J* = 5.2, 1.6 Hz, 1H, Ar-H), 7.40 (s, 1H, Ar-H), 7.39-7.35 (m, 4H, Ar-H), 7.30-7.26 (m, 1H, Ar-H), 7.23 (dd, *J* = 8.3, 1.0 Hz, 1H, Ar-H), 4.27 (s, 2H, CH₂), 2.48 (s, 3H, CH₃), 1.73 (s, 9H, 3XCH₃). ¹³C NMR (100 MHz, CDCl₃): δ 161.6, 149.8, 149.5, 142.4, 139.6, 132.9, 129.2, 128.7, 126.5, 126.3, 124.3, 121.7, 119.9, 119.5, 119.3, 115.2, 84.3, 44.7, 28.2, 21.5. MS (ESI): 399 (M+H⁺, 100). Anal calcd for C₂₆H₂₆N₂O₂: C, 78.36; H, 6.58; N, 7.03. Found C, 78.04; H, 6.91; N, 6.70.

tert-Butyl 3-(2-(4-chlorobenzyl)pyridin-4-yl)-5-methyl-1*H*-indole-1-carboxylate (**3u**). *R*_f 0.32 (EtOAc/PE = 1/6). Amorphous solid. IR (KBr) ν_{\max} : 1736, 1604, 1371, 1248, 1155 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 8.63 (d, *J* = 5.2 Hz, 1H, Ar-H), 8.09 (d, *J* = 8.4 Hz, 1H, Ar-H), 7.79 (s, 1H, Ar-H), 7.49 (s, 1H, Ar-H), 7.43 (dd, *J* = 5.2, 1.6 Hz, 1H, Ar-H), 7.37 (s, 1H, Ar-H), 7.31 (t, *J* = 1.6 Hz, 2H, Ar-H), 7.30 (s, 1H, Ar-H), 7.27 (dd, *J* = 5.2, 1.2 Hz, 1H, Ar-H), 7.22 (dd, *J* = 8.4, 1.2 Hz, 1H, Ar-H), 4.22 (s, 2H, CH₂), 2.48 (s, 3H, CH₃), 1.72 (s, 9H, 3XCH₃). ¹³C NMR (100 MHz, CDCl₃): δ 161.0, 149.9, 149.5, 142.6, 138.0, 132.9, 132.3, 130.5, 130.4, 128.7, 128.2, 126.4, 124.3, 121.6, 120.1, 119.4, 119.2, 115.3, 84.3, 44.0, 28.2, 21.4. MS (ESI): 433 (M+H⁺, 100), 435 (M+H⁺, 30). Anal calcd for C₂₆H₂₅ClN₂O₂: C, 72.13; H, 5.82; N, 6.47. Found C, 72.51; H, 5.59; N, 6.13.

tert-Butyl 3-(2-(4-chlorobenzyl)pyridin-4-yl)-6-fluoro-1*H*-indole-1-carboxylate (**3v**). *R*_f 0.29 (EtOAc/PE = 1/6). Pale yellow solid, m.p. 141-143 °C. IR (KBr) ν_{\max} : 1734, 1605, 1484, 1380, 1274, 1155 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 8.63 (d, *J* = 6.1 Hz, 1H, Ar-H), 7.95 (d, *J* = 8.8 Hz, 1H, Ar-H), 7.81 (s, 1H, Ar-H), 7.66 (dd, *J* = 8.8, 5.3 Hz, 1H, Ar-H), 7.40 (dd, *J* = 5.3, 1.6 Hz, 1H, Ar-H), 7.36 (s, 1H, Ar-H), 7.32 (d, *J* = 6.1 Hz, 1H, Ar-H), 7.30 (t, *J* = 1.6 Hz, 2H, Ar-H), 7.27

(dd, $J = 6.1, 2.3$ Hz, 1H, Ar-H), 7.08 (dd, $J = 8.8, 2.3$ Hz, 1H, Ar-H), 4.21 (s, 2H, CH₂), 1.72 (s, 9H, 3XCH₃). ¹³C NMR (100 MHz, CDCl₃): δ 161.1 (d, $J = 241.6$ Hz), 161.0, 150.0, 149.1, 142.1, 137.9, 132.4, 130.4, 128.9, 128.7, 124.4 (d, $J = 3.6$ Hz), 124.3, 121.5, 120.3 (d, $J = 9.8$ Hz), 120.0, 119.3, 111.6 (d, $J = 24.2$ Hz), 103.1 (d, $J = 28.6$ Hz), 84.9, 44.0, 28.1. MS (ESI): 437 (M+H⁺, 100), 439 (M+H⁺, 30). Anal calcd for C₂₅H₂₂ClFN₂O₂: C, 68.73; H, 5.08; N, 6.41. Found C, 68.50; H, 5.47; N, 6.62.

tert-Butyl 3-(3-benzylpyridin-4-yl)-6-fluoro-1*H*-indole-1-carboxylate (**3w**). *Rf* 0.19 (EtOAc/PE = 1/6). Amorphous solid. IR (KBr) ν_{\max} : 1739, 1602, 1374, 1222, 1153 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 8.64 (d, $J = 5.1$ Hz, 1H, Ar-H), 7.95 (d, $J = 9.3$ Hz, 1H, Ar-H), 7.79 (s, 1H, Ar-H), 7.65 (dd, $J = 8.8, 5.3$ Hz, 1H, Ar-H), 7.41-7.33 (m, 6H, Ar-H), 7.30-7.23 (m, 1H, Ar-H), 7.07 (dd, $J = 8.8, 2.4$ Hz, 1H, Ar-H), 4.26 (s, 2H, CH₂), 1.73 (s, 9H, 3XCH₃). ¹³C NMR (100 MHz, CDCl₃): δ 161.7, 161.1 (d, $J = 241.6$ Hz), 149.9, 149.2, 141.9, 139.4, 129.2, 129.1, 128.8, 128.6, 126.5, 124.3 (d, $J = 3.9$ Hz), 121.6, 120.4 (d, $J = 9.8$ Hz), 119.9, 119.5, 111.6 (d, $J = 24.2$ Hz), 103.0 (d, $J = 28.6$ Hz), 84.9, 44.8, 28.1. MS (ESI): 403 (M+H⁺, 100). Anal calcd for C₂₅H₂₃FN₂O₂: C, 74.61; H, 5.76; N, 6.96. Found C, 74.27; H, 6.13; N, 6.61.

General Procedure for the Synthesis of **4**.

To a solution of **3c** (75 mg, 0.2 mmol) in THF (1 mL) was added a methanolic solution of hydrochloric acid (0.2 mL) at 0 °C under air atmosphere. It was stirred for 2 h at room temperature and quenched with saturated aq. NaHCO₃ (1 mL) and water (5 mL). It was extracted with ethyl acetate (8 mL X 3). Combined organic layer was washed with brine and dried over Na₂SO₄. Concentration of organic layer in vacuo. The residue was purified by flash chromatography on silica gel (eluent: EtOAc/PE = 1:2) to give the corresponding product **4** (49 mg, 90%).

5-Bromo-3-(pyridin-4-yl)-1*H*-indole (**4**). *Rf* 0.15 (EtOAc/PE = 1:1). Waxy solid. IR (KBr) ν_{\max} : 3410, 1685, 1602, 1208, 802 cm⁻¹. ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.11 (s, 1H, NH), 8.55 (d, $J = 6.0$ Hz, 2H, Ar-H), 8.12 (d, $J = 1.2$ Hz, 2H, Ar-H), 7.74 (d, $J = 6.0$ Hz, 2H, Ar-H), 7.49 (d, $J = 8.6$ Hz, 1H, Ar-H), 7.32 (dd, $J = 8.6, 1.2$ Hz, 1H, Ar-H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ 149.9, 143.5, 136.4, 128.2, 126.8, 125.0, 121.8, 121.0, 114.8, 113.7, 112.8. HRESIMS calcd for [C₁₃H₉BrN₂ + H]⁺ 273.00274 (100%), 275.00069 (100%), found 273.00177 (100%), 274.99942 (100%).

General Procedure for the Synthesis of **6b**.

To a solution of indole (85 mg, 0.5 mmol) and TEMPO (55 mg, 0.35 mmol) in 4-phenylpyridine (124 mg, 0.8 mmol) was added (Boc)₂O (202 mg, 1.0 mmol) under air atmosphere and the mixture was stirred at 10 °C for 24 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (eluent: EtOAc/PE = 1:4) to yield the corresponding product **6b** (159 mg, 86%).

tert-Butyl 2-(1*H*-indol-3-yl)-4-phenylpyridine-1(2*H*)-carboxylate (**6b**). *Rf* 0.3 (EtOAc/PE = 1/8). Amorphous solid. IR (KBr) ν_{\max} : 1680, 1615, 1371, 1232, 1151 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 8.15 (s, 1H, NH), 8.03 (s, 1H, Ar-H), 7.55-7.45 (m, 2H, Ar-H), 7.43-7.30 (m, 4H, Ar-H), 7.25-7.19 (m, 2H, Ar-H), 8.64 (dt, $J = 0.8, 7.9$ Hz, 1H, Ar-H), 6.84 (s, 1H), 6.42 (s, 1H), 6.00 (s, 1H), 5.80 (s, 1H), 1.53 (s, 9H, 3XCH₃). ¹³C NMR (100 MHz, CDCl₃): δ 152.3, 139.1, 136.6, 133.1, 128.5, 127.5, 126.4, 125.9, 125.7, 124.5, 122.1, 120.8, 119.8, 117.8, 116.0, 111.1, 105.9, 81.4, 48.3, 28.3. MS (ESI): 373 (M+H⁺, 100). Anal calcd for C₂₄H₂₄N₂O₂: C, 77.39; H, 6.49; N, 7.52. Found C, 77.05; H, 6.80; N, 7.31.

General Procedure for the Indolation of Isoquinoline.

To a solution of indole (0.5 mmol), TEMPO (0.35 mmol) and isoquinoline (0.6 mmol) in THF (1 mL) was added (Boc)₂O (0.6 mmol) under air atmosphere and the mixture was stirred at room temperature for 3 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (eluent: EtOAc/PE = 1:8) to yield the corresponding product.

tert-Butyl 1-(1*H*-indol-3-yl)isoquinoline-2(1*H*)-carboxylate (**8a**). *R*_f 0.20 (EtOAc/PE = 1/10). White amorphous solid. IR (KBr) ν_{\max} : 1686, 1634, 1362, 1240, 1164, 772 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 8.00 (s, 2H, Ar-H), 7.32 (d, *J* = 7.9 Hz, 1H, Ar-H), 7.29-7.24 (br s, 1H, Ar-H), 7.21-7.11 (m, 5H, Ar-H), 6.89 (s, 1H, Ar-H), 6.77 (s, 1H, Ar-H), 6.62 (s, 1H, Ar-H), 6.00 (s, 1H, Ar-H), 1.57 (s, 9H, 3XCH₃). ¹³C NMR (100 MHz, CDCl₃): δ 152.1, 136.3, 132.5, 130.8, 127.5, 126.9, 126.8, 125.7, 125.6, 124.5, 124.4, 122.1, 120.5, 119.8, 117.8, 111.0, 108.6, 81.5, 50.8, 28.3. MS (ESI): 347 (M+H⁺, 100). Anal calcd for C₂₂H₂₂N₂O₂: C, 76.28; H, 6.40; N, 8.09. Found C, 75.91; H, 6.73; N, 7.86.

tert-Butyl 1-(2-methyl-1*H*-indol-3-yl)isoquinoline-2(1*H*)-carboxylate (**8b**). *R*_f 0.23 (EtOAc/PE = 1/8). White amorphous solid. IR (KBr) ν_{\max} : 1682, 1635, 1456, 1341, 1290, 1236, 1164, 769 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 7.87 (s, 1H, Ar-H), 7.68 (d, *J* = 6.8 Hz, 1H, Ar-H), 7.22 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.14-7.04 (m, 4H, Ar-H), 7.02 (dd, *J* = 8.0, 1.7 Hz, 2H, Ar-H), 7.00 (d, *J* = 6.8 Hz, 1H, Ar-H), 6.75 (s, 1H, Ar-H), 5.98 (d, *J* = 8.0 Hz, 1H, Ar-H), 2.58 (s, 3H, CH₃), 1.43 (s, 9H, 3XCH₃). ¹³C NMR (100 MHz, CDCl₃): δ 152.4, 135.1, 132.9, 131.8, 129.9, 127.1, 127.0, 126.8, 126.7, 126.5, 124.4, 120.9, 120.2, 119.6, 119.4, 116.7, 110.0, 106.4, 81.3, 51.7, 28.3, 12.6. MS (ESI): 361 (M+H⁺, 100). Anal calcd for C₂₃H₂₄N₂O₂: C, 76.64; H, 6.71; N, 7.77. Found C, 76.93; H, 6.57; N, 7.61.

tert-Butyl 1-(7-chloro-1*H*-indol-3-yl)isoquinoline-2(1*H*)-carboxylate (**8c**). *R*_f 0.22 (EtOAc/PE = 1/16). White amorphous solid. IR (KBr) ν_{\max} : 1694, 1634, 1446, 1342, 1241, 1122, 771 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 8.21 (s, 1H, Ar-H), 7.85 (s, 1H, Ar-H), 7.32-7.12 (m, 5H, Ar-H), 7.06 (d, *J* = 7.9 Hz, 1H, Ar-H), 6.86 (s, 1H, Ar-H), 6.76 (s, 1H, Ar-H), 6.70 (s, 1H, Ar-H), 5.99 (s, 1H, Ar-H), 1.54 (s, 9H, 3XCH₃). ¹³C NMR (100 MHz, CDCl₃): δ 152.1, 133.5, 132.1, 130.8, 127.7, 127.0, 126.9, 126.8, 125.5, 125.0, 124.6, 121.4, 120.6, 119.2, 118.9, 116.5, 108.5, 81.6, 50.7, 28.3. MS (ESI): 381 (M+H⁺, 100), 383 (M+H⁺, 30). Anal calcd for C₂₂H₂₁ClN₂O₂: C, 69.38; H, 5.56; N, 7.36. Found C, 69.25; H, 5.87; N, 7.13.

Acknowledgments

The authors are grateful to the NSF of China (Nos: 21162001 and 21202023), the National Key Technology R&D Program of China (No: 2009BAI78B01), Jiangxi Province Key Support Program (No: 2009BNB06200), Natural Science Foundation of Jiangxi Province (No: 20132BAB203007) and Jiangxi Province Office of Education Support Program (No: GJJ13666) for financial support.

References

- Recent reviews: (a) M. Bandini and A. Eichholzer, *Angew. Chem., Int. Ed.* **2009**, *48*, 9608-9644; (b) M. Shiri, M. A. Zolfigol, H. G. Kruger and Z. Tanbakouchian, *Chem. Rev.* **2010**, *110*, 2250-2293; (c) M. Shiri, *Chem. Rev.* **2012**, *112*, 3508-3549.
- J. A. Joule and K. Mills, in *Heterocyclic Chemistry*, 4th ed., Blackwell, Oxford, **2000**, pp. 63-120.
- A. R. Katritzky and R. Taylor, *Advances in Heterocyclic Chemistry*, Academic, New York, **1990**, *47*, 1-467.

- 4 Recent reviews: (a) J. A. Bull, J. J. Mousseau, J. Pelletier and A. B. Charette, *Chem. Rev.* **2012**, *112*, 2642-2713; (b) H. Andersson, R. Olsson and F. Almqvist, *Org. Biomol. Chem.* **2011**, *9*, 337-346; (c) P. C. Gros and Y. Fort, *Eur. J. Org. Chem.* **2009**, 4199-4209.
- 5 For catalytic alkylation and arylation of pyridine *N*-oxide, see: (a) S. H. Cho, S. J. Hwang and S. Chang, *J. Am. Chem. Soc.* **2008**, *130*, 9254-9256; (b) J. Wu, X. Cui, L. Chen, G. Jiang and Y. Wu, *J. Am. Chem. Soc.* **2009**, *131*, 13888-13889; (c) P. Xi, F. Yang, S. Qin, D. Zhao, J. Lan, G. Gao, C. Hu and J. You, *J. Am. Chem. Soc.* **2010**, *132*, 1822-1824; (d) H.-Q. Do, R. M. K. Khan and O. Daugulis, *J. Am. Chem. Soc.* **2008**, *130*, 15185-15192; (e) H. Andersson, M. Gustafsson, D. Bostrom, R. Olsson and F. Almqvist, *Angew. Chem., Int. Ed.* **2009**, *48*, 3288-3291; (f) M. Hussain, T. Sainte-Luce Banchelin, H. Andersson, R. Olsson and F. Almqvist, *Org. Lett.* **2013**, *15*, 54-57; (g) X. Gong, G.-Y. Song, H. Zhang and X.-W. Li, *Org. Lett.* **2011**, *13*, 1766-1769.
- 6 (a) A. Larivée, J. J. Mousseau and A. B. Charette, *J. Am. Chem. Soc.* **2008**, *130*, 52-54; (b) J. J. Mousseau, J. A. Bull and A. B. Charette, *Angew. Chem., Int. Ed.* **2010**, *49*, 1115-1118; (c) J. Bergman, *J. Heterocycl. Chem.* **1970**, *7*, 1071-1076.
- 7 For Pd-catalyzed C-H functionalization of pyridine, see: (a) L.-C. Campeau, S. Rousseaux and K. Fagnou, *J. Am. Chem. Soc.* **2005**, *127*, 18020-18021; (b) M.-C. Ye, G.-L. Gao and J.-Q. Yu, *J. Am. Chem. Soc.* **2011**, *133*, 6964-6967.
- 8 For Rh-catalyzed C-H functionalization of pyridine, see: (a) J. C. Lewis, R. G. Bergman and J. A. Ellman, *J. Am. Chem. Soc.* **2007**, *129*, 5332-5333; (b) A. M. Berman, J. C. Lewis, R. G. Bergman and J. A. Ellman, *J. Am. Chem. Soc.* **2008**, *130*, 14926-14927.
- 9 For Ni-catalyzed C-H functionalization of pyridine, see: (a) Y. Nakao, K. S. Kanyiva and T. Hiyama, *J. Am. Chem. Soc.* **2008**, *130*, 2448-2449; (b) M. Tobisu, I. Hyodo and N. Chatani, *J. Am. Chem. Soc.* **2009**, *131*, 12070-12071; (c) C. C. Tsai, W. C. Shih, C.-H. Fang, C.-Y. Li, T.-G. Ong and G.-P. Yap, *J. Am. Chem. Soc.* **2010**, *132*, 13666-13668; (d) K. S. Kanyiva, Y. Nakao and T. Hiyama, *Angew. Chem., Int. Ed.* **2007**, *46*, 8872-8874.
- 10 For Ru-catalyzed C-H functionalization of pyridine, see: (a) K. Godula, B. Sezen and D. Sames, *J. Am. Chem. Soc.* **2005**, *127*, 3648-3649; (b) T. Kawashima, T. Takao and H. Suzuki, *J. Am. Chem. Soc.* **2007**, *129*, 11006-11007.
- 11 For Ir-catalyzed C-H functionalization of pyridine, see: (a) I. A. I. Mkhaliid, D. N. Coventry, D. Albesa-Jove, A. S. Batsanov, J. A. K. Howard, R. N. Perutz and T. B. Marder, *Angew. Chem., Int. Ed.* **2006**, *45*, 489-491; (b) J. M. Murphy, X. Liao and J. F. Hartwig, *J. Am. Chem. Soc.* **2007**, *129*, 15434-15435; (c) D. F. Fischer and R. Sarpong, *J. Am. Chem. Soc.* **2010**, *132*, 5926-5927; (d) T. E. Hurst, T. K. Macklin, M. Becker, E. Hartmann, W. Kügel, J. C. Parisienne-LaSalle, A. S. Batsanov, T. B. Marder and V. Snieckus, *Chem.-Eur. J.* **2010**, *16*, 8155-8161; (e) B.-J. Li and Z.-J. Shi, *Chem. Sci.* **2011**, *2*, 488-493.
- 12 (a) R. J. Phipps, N. P. Grimster and M. J. Gaunt, *J. Am. Chem. Soc.* **2008**, *130*, 8172-8174.
- 13 Q. Chen, X. M. du Jourdin and P. Knochel, *J. Am. Chem. Soc.* **2013**, *135*, 4958-4961; (b) E. J. Corey and Y. Tian, *Org. Lett.* **2005**, *7*, 5535-5537.
- 14 R. E. Beevers, G. M. Buckley, N. Davies, J. L. Fraser, F. C. Galvin, D. R. Hannah, A. F. Haughan, K. Jenkins, S. R. Mack, W. R. Pitt, A. J. Ratcliffe, M. D. Richard, V. Sabin, A. Sharpe and S. C. Williams, *Bioorg. Med. Chem. Lett.* **2006**, *16*, 2535-2538.